FDA proposes blocking compounded GLP‑1s

The U.S. Food and Drug Administration said on April 30 that it wants to keep semaglutide, tirzepatide and liraglutide off the 503B Bulks List, a move that would block outsourcing facilities from routinely compounding those drugs from bulk ingredients if finalized. The proposal targets the large-scale compounding pathway used by 503B facilities, not the branded drugs themselves. FDA said it found no clinical need for outsourcing facilities to compound the three GLP-1 medicines from bulk substances. The agency opened the proposal for public comment in a Federal Register notice published on May 1. ### Which drugs did FDA target, exactly? Semaglutide, tirzepatide and liraglutide are the three substances named in the proposal, according to FDA’s April 30 announcement. Those active ingredients are used in blockbuster diabetes and obesity products including Novo Nordisk’s Ozempic, Wegovy, Victoza and Saxenda, and Eli Lilly’s Mounjaro and Zepbound. The May 1 Federal Register notice said FDA is proposing not to include those three bulk drug substances on the 503B Bulks List after reviewing nominations for their inclusion. The agency said additional nominated substances remain under review in separate notices. (fda.gov) ### Why does the 503B Bulks List matter to compounders? Section 503B governs outsourcing facilities that make compounded drugs at larger scale. FDA said those facilities generally cannot compound using bulk drug substances unless the ingredient appears on the 503B Bulks List or the compounded drug is on FDA’s drug shortage list at the time of compounding, distribution and dispensing. (federalregister.gov) Marty Makary, the FDA commissioner, said in the agency release that “when FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.” He said the proposal was meant to protect patients and preserve the drug approval process while allowing public input. (fda.gov) ### How is this different from the earlier shortage fight? Demand for GLP-1 drugs surged beginning in 2022, and shortages created a legal opening for compounders to make copies while the branded products were listed as scarce, according to Pharmacy Times. That publication said compounded versions often sold for about $150 to $300 a month, compared with branded products priced above $1,000 a month. (fda.gov) By late 2024 and early 2025, FDA had declared the tirzepatide and semaglutide shortages resolved and set wind-down enforcement deadlines, Pharmacy Times reported. The new 503B proposal addresses a separate route — bulk-substance compounding by outsourcing facilities — and would remain relevant even outside a shortage. ### What could this mean for patients using compounded GLP-1s? (pharmacytimes.com) Pharmacy Times said the proposal would remove the bulks-list pathway for large-scale compounding of these GLP-1 drugs and described the move as leaving those products with “no regulatory future” in the 503B channel if finalized. The publication also cited more than 455 semaglutide adverse-event reports and more than 320 tirzepatide reports, along with dosing errors tied to multidose vials and counterfeit supply concerns. (pharmacytimes.com) Coverage pressure has also been building around weight-loss GLP-1s. The American Journal of Managed Care reported that insurers have been dropping coverage for costly obesity-drug prescriptions, increasing out-of-pocket costs for some patients, while The Washington Post reported on May 23 that clinicians are seeing eating-disorder patients using GLP-1 drugs and warning about risks in those settings. (pharmacytimes.com) ### Does this shut down all compounding of these drugs? The FDA proposal is aimed at 503B outsourcing facilities using bulk active ingredients. The agency’s notice does not ban the FDA-approved branded products, and the final regulatory effect will depend on whether FDA adopts the proposal after reviewing comments. (ajmc.com) The Federal Register notice published on May 1 says electronic or written comments must be submitted by June 30, 2026. FDA said it will review those comments before making a final determination. (federalregister.gov) (fda.gov)